Open Access Green as soon as Postprint is submitted to ZB.
A divergent population of autoantigen-responsive CD4+ T cells in infants prior to β cell autoimmunity.
Sci. Transl. Med. 9:eaaf8848 (2017)
Autoimmune diabetes is marked by sensitization to β cell self-antigens in childhood. We longitudinally followed at-risk children from infancy and performed single-cell gene expression in β cell antigen-responsive CD4(+) T cells through pre- and established autoimmune phases. A striking divergence in the gene signature of β cell antigen-responsive naïve CD4(+) T cells from children who developed β cell autoimmunity was found in infancy, well before the appearance of β cell antigen-specific memory T cells or autoantibodies. The signature resembled a pre-T helper 1 (TH1)/TH17/T follicular helper cell response with expression of CCR6, IL21, TBX21, TNF, RORC, EGR2, TGFB1, and ICOS, in the absence of FOXP3, IL17, and other cytokines. The cells transitioned to an IFNG-TH1 memory phenotype with the emergence of autoantibodies. We suggest that the divergent naïve T cell response is a consequence of genetic or environmental priming during unfavorable perinatal exposures and that the signature will guide future efforts to detect and prevent β cell autoimmunity.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Diabetes-associated Autoantibodies; Multiple Islet Autoantibodies; Helper-cells; Increased Risk; Cutting Edge; Type-1; Children; Differentiation; Seroconversion; Activation
ISSN (print) / ISBN
1946-6234
e-ISSN
1946-6242
Journal
Science Translational Medicine
Quellenangaben
Volume: 9,
Issue: 378,
Article Number: eaaf8848
Publisher
American Association for the Advancement of Science (AAAS)
Publishing Place
Washington
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Diabetes Research Type 1 (IDF)
Institute of Diabetes and Obesity (IDO)
Institute for Pancreatic Beta Cell Research (IPI)
Institute of Diabetes and Obesity (IDO)
Institute for Pancreatic Beta Cell Research (IPI)